CN111296759A - 一种具有保护胃黏膜功能的组合物、应用及其制备方法 - Google Patents
一种具有保护胃黏膜功能的组合物、应用及其制备方法 Download PDFInfo
- Publication number
- CN111296759A CN111296759A CN202010107236.0A CN202010107236A CN111296759A CN 111296759 A CN111296759 A CN 111296759A CN 202010107236 A CN202010107236 A CN 202010107236A CN 111296759 A CN111296759 A CN 111296759A
- Authority
- CN
- China
- Prior art keywords
- soybeans
- composition
- gastric mucosa
- protecting
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 210000001156 gastric mucosa Anatomy 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 47
- 244000068988 Glycine max Species 0.000 claims abstract description 47
- 239000000843 powder Substances 0.000 claims abstract description 43
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 37
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 37
- 230000000694 effects Effects 0.000 claims abstract description 26
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 57
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 29
- 229920002752 Konjac Polymers 0.000 claims description 26
- 235000010485 konjac Nutrition 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 21
- 239000002244 precipitate Substances 0.000 claims description 20
- 235000019764 Soybean Meal Nutrition 0.000 claims description 18
- 239000004455 soybean meal Substances 0.000 claims description 18
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 17
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 238000004537 pulping Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000001694 spray drying Methods 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000002699 waste material Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 238000011081 inoculation Methods 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 208000018556 stomach disease Diseases 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 238000010411 cooking Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 230000003472 neutralizing effect Effects 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 230000006196 deacetylation Effects 0.000 claims description 2
- 238000003381 deacetylation reaction Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 241000590002 Helicobacter pylori Species 0.000 abstract description 10
- 229940037467 helicobacter pylori Drugs 0.000 abstract description 10
- 241001052560 Thallis Species 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 9
- 231100000397 ulcer Toxicity 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 208000007107 Stomach Ulcer Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 201000005917 gastric ulcer Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229960000381 omeprazole Drugs 0.000 description 3
- 208000011906 peptic ulcer disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000037384 Clostridium Infections Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010054236 Clostridium difficile infection Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067994 Mucosal atrophy Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229940106307 glutamine 200 mg Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
- A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
- A23L19/115—Konjak; Konntaku
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/137—Delbrueckii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开一种具有保护胃黏膜功能的组合物、应用及其制备方法,本发明所述的具有保护胃黏膜功能的组合物由发酵大豆粉、灭活罗伊氏乳杆菌、谷氨酰胺、壳寡糖、魔芋提取物制备得到。发酵大豆粉是由大豆粉经德氏乳杆菌保加利亚亚种发酵而得的物质,经热灭活的罗伊氏乳杆菌的菌体能够识别幽门螺旋杆菌的表面结构。本发明提供的组合物能对胃黏膜起到保护作用,且安全无副作用。
Description
技术领域
本发明属于医疗保健领域,特别涉及一种具有保护胃黏膜功能的组合物及其制备方法。
背景技术
消化性溃疡是一种穿透黏膜肌层的胃肠道黏膜的局限性损伤,常发生于胃(胃溃疡)或十二指肠近端数厘米(十二指肠溃疡)。几乎所有溃疡均由幽门螺旋杆菌或使用NSAID引起。典型症状包括上腹部烧灼样疼痛,进食后缓解。诊断依靠内镜及幽门螺旋杆菌相关检查,治疗包括抑酸、清除幽门螺旋杆菌(如果存在)和避免使用NSAID。治疗消化性溃疡的首要目标是清除溃疡面、恢复黏膜功能。
目前市场上出现的治疗胃黏膜损伤的药物有质子泵抑制剂(奥美拉唑等)、抑酸剂(碳酸氢钠等)、胃黏膜保护剂(枸橼酸铋钾等)和抗幽门螺旋杆菌药物等等。大多数患者会选用化学药物治疗胃黏膜的损伤,然而化学药物除了有治疗疾病的作用外,一般还会刺激胃肠道,使原本受损的胃肠粘膜进一步受损,副作用大,长时间使用很容易破坏机体的平衡,使病情加重,还有可能引起其他疾病的产生。例如,服用奥美拉唑产生的不良反应有腹泻、头痛、恶心、胃肠胀气及便秘,有些病例中可发生胃黏膜细胞增生和萎缩性胃炎,服用超过8周会增加艰难梭菌感染及骨折的风险;枸橼酸铋钾也不宜长期服用,当血铋浓度超过0.1微克/毫升的时候,有可能导致铋性脑病,初期表现为慢性头痛、失眠、精神异常等,亦可突然发生明显的脑病症状,如精神错乱、肌肉强直、运动失调、构音障碍、幻觉、惊厥等;长期大量服用克拉霉素会引起肝肾损伤以及心律失常等严重不良反应。
发明内容
本发明的目的是提供一种具有保护胃黏膜功能的组合物,能对胃黏膜起到保护作用,且安全无副作用,是一种良好的胃病患者的食品组合物。
有必要的,提供上述具有保护胃黏膜功能的组合物的制备方法。
一种具有保护胃黏膜功能的组合物,包括以下成分:
发酵大豆粉、灭活罗伊氏乳杆菌、谷氨酰胺、壳寡糖、魔芋提取物。
优选地,所述具有保护胃黏膜功能的组合物,其特征在于按其重量份包括以下成分:
发酵大豆粉30-50份、灭活罗伊氏乳杆菌1-2份、谷氨酰胺10-13份、壳寡糖7-8份、魔芋提取物30-52份。
更优选地,所述具有保护胃黏膜功能的组合物,其特征在于按其重量份包括以下成分:
发酵大豆粉30-41份、灭活罗伊氏乳杆菌1-2份、谷氨酰胺12-13份、壳寡糖7-8份、魔芋提取物38-48份。
优选地,所述发酵大豆粉、灭活罗伊氏乳杆菌、谷氨酰胺、壳寡糖、魔芋提取物的重量份相加之和为100份。
其中,所述发酵大豆粉由以下方法制得:
将大豆洗净称重,用水浸泡12小时,然后130℃蒸煮1小时后冷却至37℃,加入大豆重量2%的葡萄糖,然后加入活性为5亿CFU/mL德氏乳杆菌保加利亚亚种菌种液,接种量为4%,在37℃培养16小时后取出,用打浆机制浆后加入1mol/L的氢氧化钠溶液调节溶液的pH值至10,离心分离收集上清液用1mol/L的盐酸调节pH值为4.5,离心分离收集沉淀,向沉淀中加入1mol/L的氢氧化钠溶液中和沉淀后喷雾干燥得到发酵大豆粉。
本申请所述的接种量是指移入种子液的体积和接种后培养液体积的比例。
其中,所述发酵大豆粉的蛋白质含量为50%至55%,检测方法是《GB 5009.5-2010食品安全国家标准食品中蛋白质的测定》。
其中,所述灭活罗伊氏乳杆菌由以下方法制得:
取活性为2000亿CFU/g的发酵完毕的罗伊氏乳杆菌菌粉,加入9倍水并混合均匀,然后用谷氨酸调节pH至2(此为灭活处理的关键步骤),搅拌10分钟后停止搅拌,喷雾干燥得到灭活罗伊氏乳杆菌。
其中,所述魔芋提取物由以下方法制得:
将鲜魔芋清洗、去皮,切丁,加入鲜魔芋重量0.9倍的柠檬酸酒精水溶液,所述柠檬酸酒精水溶液中含有2wt%的柠檬酸,含有76wt%的乙醇,在打浆机中搅拌3min后,在550r/min下,离心2min将湿粉和废液分离;在分离出的湿粉中,加入湿粉重量0.9倍的柠檬酸酒精水溶液溶解搅拌3min,在550r/min下,离心2min将湿粉和废液分离;将两次所得湿粉进行真空干燥,干燥条件为:真空度0.1MPa,温度60℃,至水分含量小于5%时停止干燥,得到魔芋提取物。其中,所述壳聚糖的脱乙酰度大于95%,分子量为50kDa到80kDa之间。
本发明还提供一种如上所述的具有保护胃黏膜功能的组合物在制备预防或治疗胃病的保健品中的应用。
本发明还提供了一种如相所述具有保护胃黏膜功能的组合物在制备预防或治疗胃病的药品中的应用。
上述胃病为与胃黏膜损伤有关的疾病,包括急性胃炎、慢性胃炎、胃溃疡、十二指肠溃疡、胃十二指肠复合溃疡。
本发明所述的组合物均为食品配料或食品添加剂,其对胃粘膜作用缓和、不会产生类似于药品的不良反应和副作用。
进一步地,本发明提供了一种如上所述的具有保护胃黏膜功能的组合物的制备方法,包括以下步骤:
1)、备料
发酵大豆粉的制备:将大豆洗净称重,用水浸泡12小时,然后130℃蒸煮1小时后冷却至37℃,加入大豆重量2%的葡萄糖,然后加入活性为5亿CFU/mL德氏乳杆菌保加利亚亚种菌种液,接种量为25,在37℃培养16小时后取出,用打浆机制浆后加入1mol/L的氢氧化钠溶液调节溶液的pH值至10,离心分离收集上清液用1mol/L的盐酸调节pH值为4.5,离心分离收集沉淀,向沉淀中加入1mol/L的氢氧化钠溶液中和沉淀后喷雾干燥得到发酵大豆粉;
所述灭活罗伊氏乳杆菌的制备:取活性为2000亿CFU/g的发酵完毕的罗伊氏乳杆菌菌粉,加入9倍水并混合均匀,然后用谷氨酸调节pH至2,搅拌10分钟后停止搅拌,喷雾干燥得到灭活罗伊氏乳杆菌;
魔芋提取物的制备:
将鲜魔芋清洗、去皮,切丁,加入鲜魔芋重量0.9倍的柠檬酸酒精水溶液,所述柠檬酸酒精水溶液中含有2wt%的柠檬酸,含有76wt%的乙醇,在打浆机中搅拌3min后,在550r/min下,离心2min将湿粉和废液分离;在分离出的湿粉中,加入湿粉重量0.9倍的柠檬酸酒精水溶液溶解搅拌3min,在550r/min下,离心2min将湿粉和废液分离;将两次所得湿粉进行真空干燥,干燥条件为:真空度0.1MPa,温度60℃,至水分含量小于5%时停止干燥,得到魔芋提取物;
2)、按重量份将发酵大豆粉、灭活罗伊氏乳杆菌、谷氨酰胺、壳寡糖、魔芋提取物混合均匀,得到具有保护胃黏膜功能的组合物。
本发明与现有技术相比,本发明所述的组合物具有较好的胃黏膜保护作用,由发酵大豆粉、灭活罗伊氏乳杆菌、谷氨酰胺、壳寡糖、魔芋提取物制备得到,五种成分有很好的协同增效作用,由与单一组分相比,溃疡抑制率要远远高于同等剂量的任一单一组分。
本发明所选择的成分中,发酵大豆粉是由大豆粉经德氏乳杆菌保加利亚亚种发酵而得的物质,其含有多肽、微生物代谢产物,可以快速缓解胃灼热和十二指肠疼痛。经热灭活的罗伊氏乳杆菌的菌体能够识别幽门螺旋杆菌的表面结构,使其形成共聚物后经过人体消化道排泄,使胃里面定植的幽门螺旋杆菌水平下降。壳寡糖对幽门螺旋杆菌有抑制作用,而幽门螺旋杆菌会引发胃炎、消化道溃疡,因此壳聚糖对幽门螺旋杆菌引起的胃炎和胃溃疡有治疗作用。谷氨酰胺是胃肠粘膜细胞特殊的营养物质,具有维持粘膜组织的结构,防止粘膜萎缩的功能。魔芋中的葡甘聚糖与水形成粘稠胶状物之后,成为保护性薄膜,从而隔绝胃酸、酶及食物对溃疡粘膜的侵蚀作用,促进溃疡组织的修复和愈合。
本发明所述的组合物均为食品配料或食品添加剂,其对胃粘膜作用缓和、不会产生类似于药品的不良反应和副作用。
具体实施方式
为了使本技术领域的人员更好地理解本发明方案,下面结合具体实施方式对本发明作进一步的详细说明。
原料说明
发酵大豆粉的制备:将大豆洗净称重,用水浸泡12小时,然后130℃蒸煮1小时后冷却至37℃,加入相当于大豆重量2%的葡萄糖,然后加入活性为5亿CFU/mL德氏乳杆菌保加利亚亚种菌种液,接种量为25,在37℃培养16小时后取出,用打浆机制浆后加入1mol/L的氢氧化钠溶液调节溶液的pH值至10,离心分离收集上清液用1mol/L的盐酸调节pH值为4.5,离心分离收集沉淀,向沉淀中加入1mol/L的氢氧化钠溶液中和沉淀后喷雾干燥得到发酵大豆粉。
灭活罗伊氏乳杆菌的制备:取活性为2000亿CFU/g的发酵完毕的罗伊氏乳杆菌菌粉,加入9倍水并混合均匀,然后用谷氨酸调节pH至2,搅拌10分钟后停止搅拌,喷雾干燥得到灭活罗伊氏乳杆菌。
魔芋提取物的制备:将鲜魔芋清洗、去皮,切丁,加入加有2%柠檬酸,浓度为76%,0.9倍魔芋量的酒精中,在打浆机中搅拌3min后,在550r/min下,离心2min将湿粉和废液分离;再将分离出的湿粉用0.9倍魔芋量的有2%柠檬酸,浓度为76%酒精溶解搅拌,打浆及分离方法同上;将两次所得湿粉进行真空干燥(条件为:真空度0.1MPa,温度60℃)至水分含量小于5%时停止干燥,得到魔芋提取物。
壳聚糖由青岛云宙生物科技有限公司生产提供,型号为DAC95。
德氏乳杆菌保加利亚亚种菌种由上海交大昂利股份有限公司生产提供,活性为500亿CFU/g。
罗伊氏乳杆菌原料由上海交大昂利股份有限公司生产提供,活性为2000亿CFU/g。
谷氨酰胺由河北华阳生物科技有限公司生产提供,纯度为99%(以干燥品计)。
实施例1-3和对比例1-6
按表1所示的重量份将发酵大豆粉、灭活罗伊氏乳杆菌、谷氨酰胺、壳寡糖、魔芋提取物混合均匀,得到具有保护胃黏膜功能的组合物。
表1实施例和对比例的配方表
发酵大豆粉 | 灭活罗伊氏乳杆菌 | 谷氨酰胺 | 壳寡糖 | 魔芋提取物 | |
实施例1 | 30 | 1 | 13 | 8 | 48 |
实施例2 | 41 | 2 | 12 | 7 | 38 |
实施例3 | 35 | 1.5 | 12.5 | 7.5 | 43.5 |
对比例1 | 0 | 1.5 | 12.5 | 7.5 | 43.5 |
对比例2 | 60 | 1.5 | 12.5 | 7.5 | 43.5 |
对比例3 | 35 | 0 | 12.5 | 7.5 | 43.5 |
对比例4 | 35 | 1.5 | 0 | 7.5 | 43.5 |
对比例5 | 35 | 1.5 | 12.5 | 0 | 43.5 |
对比例6 | 35 | 1.5 | 12.5 | 7.5 | 0 |
对比例8 | 35 | 1.5 | 12.5 | 7.5 | 43.5 |
对比例7
将发酵大豆粉35重量份、罗伊氏乳杆菌1.5、谷氨酰胺12.5、壳寡糖7.5、魔芋提取物43.5混合均匀,得到具有保护胃黏膜功能的组合物。
对比例8
按表1所示的重量份将发酵大豆粉、灭活罗伊氏乳杆菌、谷氨酰胺、壳寡糖、魔芋提取物混合均匀,得到具有保护胃黏膜功能的组合物:
其中,灭活罗伊氏乳杆菌由以下方法制备:取活性为2000亿CFU/g的发酵完毕的罗伊氏乳杆菌菌粉,加入9倍水并混合均匀,然后用谷氨酸调节pH至4,搅拌10分钟后停止搅拌,喷雾干燥得到灭活罗伊氏乳杆菌。
将实施例1-3和对比例1-8制得的组合物进行功效评价
实验材料:实施例1-3和对比例1-8制得的组合物,带标尺的解剖镜、微量注射器,冰醋酸,实验动物(SD健康大鼠)
剂量选择:按照实施例2和实施例3的配方,加纯净水稀释溶解,充分混匀后,配成20mg/mL的溶液,放入冰箱4℃保存,按照大鼠体重200mg/kg的剂量给药。
实验方法:采用冰醋酸浸渍慢性胃溃疡模型法
取SD大鼠120只,随机分成15组,每组8只,分别为正常对照组(生理盐水代替冰醋酸)、模型对照组(生理盐水5mL/kg)、发酵大豆粉组(发酵大豆粉200mg/kg)、灭活罗伊氏乳杆菌组(灭活罗伊氏乳杆菌200mg/kg)、谷氨酰胺组(谷氨酰胺200mg/kg)、壳寡糖组(壳寡糖200mg/kg)、魔芋提取物组(魔芋提取物200mg/kg)、实施例1-3和对比例1-8配方组(剂量均为200mg/kg)。将禁食不禁水24小时后的动物用乙醚麻醉,每鼠实施剖腹手术,将内径5mm、长30mm的玻璃管垂直放置于胃体部粘膜面上,向管腔内加入冰醋酸0.2mL,1.5分钟后用棉签蘸出冰醋酸,缝合手术切口,术后正常饮食、水。第二天开始给受试物,连续给受试样品样品14天后,解剖取出胃,并用甲醛固定,测量胃溃疡面积,以溃疡面积的平均值作为评价损伤指标,将结果列于表2中。
表2组合物功效评价
剂量(mg/kg) | 溃疡面积平均值(mm2) | |
正常组 | —— | 0 |
对照组 | 生理盐水5mL/kg | 28.26±1.05 |
实施例1 | 200 | 6.08±0.56 |
实施例2 | 200 | 5.24±0.66 |
实施例3 | 200 | 6.74±0.47 |
对比例1 | 200 | 9.14±0.56 |
对比例2 | 200 | 8.52±0.66 |
对比例3 | 200 | 7.33±0.68 |
对比例4 | 200 | 8.54±0.72 |
对比例5 | 200 | 7.69±0.78 |
对比例6 | 200 | 7.14±0.49 |
对比例7 | 200 | 9.14±0.59 |
对比例8 | 200 | 8.74±0.62 |
发酵大豆粉组 | 200 | 12.48±1.95 |
灭活罗伊氏乳杆菌组 | 200 | 14.20±0.46 |
谷氨酰胺组 | 200 | 10.64±0.36 |
壳寡糖组 | 200 | 16.84±1.47 |
魔芋提取物组 | 200 | 15.37±0.95 |
由表2的实验结果可以看出,受试物能明显降低冰醋酸浸渍所引起的胃粘膜损伤,抑制溃疡的形成,促进胃粘膜的恢复。实施例的效果比任一单独组分的效果都好,且明显优于对比例的效果。说明本发明的组合物组分之间具有很好的协同治疗作用。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (10)
1.一种具有保护胃黏膜功能的组合物,其特征在于包括以下成分:
发酵大豆粉、灭活罗伊氏乳杆菌、谷氨酰胺、壳寡糖、魔芋提取物。
2.如权利要求1所述的具有保护胃黏膜功能的组合物,其特征在于按其重量份包括以下成分:
发酵大豆粉30-41份、灭活罗伊氏乳杆菌1-2份、谷氨酰胺12-13份、壳寡糖7-8份、魔芋提取物38-48份。
3.如权利要求2所述的具有保护胃黏膜功能的组合物,其特征在于:
所述发酵大豆粉由以下方法制得:
将大豆洗净称重,用水浸泡12小时,然后130℃蒸煮1小时后冷却至37℃,加入大豆重量2%的葡萄糖,然后加入活性为5亿CFU/mL德氏乳杆菌保加利亚亚种菌种液,接种量为4%,在37℃培养16小时后取出,用打浆机制浆后加入1mol/L的氢氧化钠溶液调节溶液的pH值至10,离心分离收集上清液用1mol/L的盐酸调节pH值为4.5,离心分离收集沉淀,向沉淀中加入1mol/L的氢氧化钠溶液中和沉淀后喷雾干燥得到发酵大豆粉。
4.如权利要求2所述的具有保护胃黏膜功能的组合物,其特征在于:
所述发酵大豆粉的蛋白质含量为50%至55%。
5.如权利要求2所述的具有保护胃黏膜功能的组合物,其特征在于:
所述灭活罗伊氏乳杆菌由以下方法制得:
取活性为2000亿CFU/g的发酵完毕的罗伊氏乳杆菌菌粉,加入9倍水并混合均匀,然后用谷氨酸调节pH至2,搅拌10分钟后停止搅拌,喷雾干燥得到灭活罗伊氏乳杆菌。
6.如权利要求2所述的具有保护胃黏膜功能的组合物,其特征在于:
所述魔芋提取物由以下方法制得:
将鲜魔芋清洗、去皮,切丁,加入鲜魔芋重量0.9倍的柠檬酸酒精水溶液,所述柠檬酸酒精水溶液中含有2wt%的柠檬酸,含有76wt%的乙醇,在打浆机中搅拌3min后,在550r/min下,离心2min将湿粉和废液分离;在分离出的湿粉中,加入湿粉重量0.9倍的柠檬酸酒精水溶液溶解搅拌3min,在550r/min下,离心2min将湿粉和废液分离;将两次所得湿粉进行真空干燥,干燥条件为:真空度0.1MPa,温度60℃,至水分含量小于5%时停止干燥,得到魔芋提取物。
7.如权利要求2所述的具有保护胃黏膜功能的组合物,其特征在于:
所述壳聚糖的脱乙酰度大于95%,分子量为50kDa到80kDa之间。
8.如权利要求1-7任一所述的具有保护胃黏膜功能的组合物在制备预防或治疗胃病的保健品中的应用。
9.如权利要求1-7任一所述的具有保护胃黏膜功能的组合物在制备预防或治疗胃病的药品中的应用。
10.一种如权利要求1-7任一所述的具有保护胃黏膜功能的组合物的制备方法,其特征在于包括以下步骤:
1)、备料
将大豆洗净称重,用水浸泡12小时,然后130℃蒸煮1小时后冷却至37℃,加入大豆重量2%的葡萄糖,然后加入活性为5亿CFU/mL德氏乳杆菌保加利亚亚种菌种液,接种量为4%,在37℃培养16小时后取出,用打浆机制浆后加入1mol/L的氢氧化钠溶液调节溶液的pH值至10,离心分离收集上清液用1mol/L的盐酸调节pH值为4.5,离心分离收集沉淀,向沉淀中加入1mol/L的氢氧化钠溶液中和沉淀后喷雾干燥得到发酵大豆粉;
所述灭活罗伊氏乳杆菌的制备:取活性为2000亿CFU/g的发酵完毕的罗伊氏乳杆菌菌粉,加入9倍水并混合均匀,然后用谷氨酸调节pH至2,搅拌10分钟后停止搅拌,喷雾干燥得到灭活罗伊氏乳杆菌;
魔芋提取物的制备:
将鲜魔芋清洗、去皮,切丁,加入鲜魔芋重量0.9倍的柠檬酸酒精水溶液,所述柠檬酸酒精水溶液中含有加入加有2wt%的柠檬酸,含有浓度为76wt%的乙醇,0.9倍魔芋量的酒精中,在打浆机中搅打搅拌3min后,在550r/min下,离心2min将湿粉和废液分离;再将在分离出的湿粉中,加入湿粉重量0.9倍的柠檬酸酒精水溶液用0.9倍魔芋量的有2%柠檬酸,浓度为76%酒精溶解搅打搅拌3min,在550r/min下,离心2min将湿粉和废液分离打浆及分离方法同上;将两次所得湿粉进行真空干燥(,干燥条件为:真空度0.1MPa,温度60℃),至水分含量小于5%时停止干燥,得到魔芋提取物;
2)、按重量份将发酵大豆粉、灭活罗伊氏乳杆菌、谷氨酰胺、壳寡糖、魔芋提取物混合均匀,得到具有保护胃黏膜功能的组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010107236.0A CN111296759A (zh) | 2020-02-21 | 2020-02-21 | 一种具有保护胃黏膜功能的组合物、应用及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010107236.0A CN111296759A (zh) | 2020-02-21 | 2020-02-21 | 一种具有保护胃黏膜功能的组合物、应用及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111296759A true CN111296759A (zh) | 2020-06-19 |
Family
ID=71160260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010107236.0A Pending CN111296759A (zh) | 2020-02-21 | 2020-02-21 | 一种具有保护胃黏膜功能的组合物、应用及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111296759A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105962086A (zh) * | 2016-05-06 | 2016-09-28 | 广州能靓生物技术有限公司 | 一种组合物及其在制备缓解胃部不适的保健品中的应用 |
CN106306731A (zh) * | 2015-06-16 | 2017-01-11 | 陕西理工学院 | 一种魔芋精粉无硫湿法综合加工方法 |
CN106820151A (zh) * | 2016-12-22 | 2017-06-13 | 北京康比特体育科技股份有限公司 | 一种双壳复合保健组合物、制备方法及应用 |
CN106901344A (zh) * | 2017-03-16 | 2017-06-30 | 北京知蜂堂健康科技股份有限公司 | 一种缓解胃痛腹痛的组合物及其应用 |
CN110150515A (zh) * | 2018-03-01 | 2019-08-23 | 南昌顶津食品有限公司 | 一种缓解胃溃疡的魔芋饮料及其制备方法和应用 |
-
2020
- 2020-02-21 CN CN202010107236.0A patent/CN111296759A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106306731A (zh) * | 2015-06-16 | 2017-01-11 | 陕西理工学院 | 一种魔芋精粉无硫湿法综合加工方法 |
CN105962086A (zh) * | 2016-05-06 | 2016-09-28 | 广州能靓生物技术有限公司 | 一种组合物及其在制备缓解胃部不适的保健品中的应用 |
CN106820151A (zh) * | 2016-12-22 | 2017-06-13 | 北京康比特体育科技股份有限公司 | 一种双壳复合保健组合物、制备方法及应用 |
CN106901344A (zh) * | 2017-03-16 | 2017-06-30 | 北京知蜂堂健康科技股份有限公司 | 一种缓解胃痛腹痛的组合物及其应用 |
CN110150515A (zh) * | 2018-03-01 | 2019-08-23 | 南昌顶津食品有限公司 | 一种缓解胃溃疡的魔芋饮料及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
成虹: "《幽门螺杆菌及其相关疾病诊疗成虹2020观点》", 31 December 2019, 科学技术文献出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI787950B (zh) | 用於預防、緩解或治療冠狀病毒感染的包括杜英萃取物作為活性成分之藥物組成物以及食品組成物 | |
EP2098240B1 (en) | Agent for promoting healing of living body | |
KR102084973B1 (ko) | 엔테로코커스 패칼리스를 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 | |
KR100699790B1 (ko) | 댕댕이나무 추출물을 포함하는 간 질환 예방 및 치료효과를 가지는 약제학적 조성물 | |
JP2000191542A (ja) | 骨粗鬆症予防、治療剤 | |
JPH0930987A (ja) | 難治性の潰瘍、胃炎及び皮膚炎の治療乃至予防用製剤 | |
WO2015160181A1 (ko) | 황칠 추출물을 포함하는 혈관 평활근세포 이상 증식 및 이동성 질환 또는 혈관 내막증식 질환의 예방 또는 치료용 조성물 | |
JPS62103022A (ja) | 化学療法剤の副作用低減化剤 | |
US20060240120A1 (en) | Composition for lowering blood glucose | |
CN113413402B (zh) | 梅花草提取物在制备治疗幽门螺杆菌感染疾病药物中的应用 | |
JP2002322079A (ja) | ピロリ菌除菌組成物及びピロリ菌抗菌、除菌剤 | |
CN111296759A (zh) | 一种具有保护胃黏膜功能的组合物、应用及其制备方法 | |
JP4633367B2 (ja) | 抗ヘリコバクター・ピロリ剤 | |
JP4644834B2 (ja) | ハマナス類由来のα−アミラーゼ阻害剤、α−グルコシダーゼ阻害剤、グルコース吸収阻害剤およびその利用 | |
EP1525887A1 (en) | Drugs including anticancer agents and immunopotentiators and health foods and drinks | |
CN110559304B (zh) | 一种化脓性关节炎治疗药物组合物 | |
KR20180082921A (ko) | 위염 또는 소화성궤양 예방 또는 치료용 조성물 | |
JPH01172333A (ja) | 豚の溶連菌感染症の予防及び治療剤 | |
WO2016072507A1 (ja) | 消化性潰瘍の予防又は治療剤,及び予防又は治療のための食品添加物,iNOS発現抑制剤及びCOX-2発現抑制剤 | |
JP3813808B2 (ja) | ケフィアを用いた糖尿病治療剤の製造方法 | |
CN108309969B (zh) | 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途 | |
CN112741826A (zh) | 氯硝柳胺的新应用 | |
KR100415591B1 (ko) | 위장내 헬리코박터 피로리 감염균의 감소 및 증식억제능이 있는 요구르트 조성물 | |
JP6476043B2 (ja) | 消化性潰瘍の予防又は治療剤,及び予防又は治療のための食品添加物 | |
RU2780346C1 (ru) | Терапевтический агент против коронавируса, включающий экстракт elaeocarpus sylvestris |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200619 |
|
RJ01 | Rejection of invention patent application after publication |